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1. Introduction 
Sarcoidosis is an illness of granulomatous inflammation with multi-organ association. While 
most individuals exhibit pulmonary pathology, renal involvement is not without prevalence 
or significance. This chapter will review the current epidemiology of the disease and explore 
the two major pathways in the pathogenesis of renal sarcoidosis, mainly granulomatous 
deposition and deranged calcium management. With these concepts addressed, further 
inquiries into intrinsic renal disease will be provided along with explanations of 
renovascular complications, obstructive nephropathy, and transplant pathology. Each 
ailment will be accompanied by common presentation, more detailed pathophysiology, 
appropriate diagnostics, and current treatment recommendations. This chapter will seek to 
purvey a comprehensive but concise exploration of renal sarcoidosis.  
2. Epidemiology & susceptibility 
Sarcoidosis can affect a wide range of racial and ethnic groups but it has high prevalence in 
northern European countries, Japan, and the United States1. Certain countries have skewed 
incidences, for example: black Americans are three times more likely than white Americans 
to develop the disease (Iannuzzi et al. 2007). However, across the racial and ethnic groups, 
females are more prone to the illness than males (Iannuzzi et al. 2007). The disease manifests 
itself typically in patients less than 50 years of age and mainly in the third of fourth decade 
of life (Iannuzzi et al. 2011). A patient with a first degree relative with the disease has a five-
fold increase of developing sarcoidosis. Nevertheless, this risk still does not exceed 1% 
(Iannuzzi et al. 2011). Patient susceptibility also increases with certain associations of 
genetics and environmental factors. Discoveries into HLA gene products and the 
butyrophilin-like2 (BTNL2) gene are the latest areas of genetic interests (Iannuzzi et al. 
2007). A variety of environmental triggers including wood-burning stoves, tree pollen, 
inorganic particles, insecticides, and mold have also been scrutinized in addition to 
mycobacteria and propionibacteria antigens (Iannuzzi et al. 2007, 2011). In fact, combinations 
of genetic and environmental activators have also been examined, for example: HLA-DQB1 
and water damage or high humanity in the workplace (Iannuzzi et al. 2007). However, it 
seems that a ubiquitous number of agents may initiate a similar immunologic pathway that 
is pathognomonic for sarcoidosis.  
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3. Manifestations & pathogenesis 
Sarcoidosis mainly affects the pulmonary system, with an over 90% occurrence rate in the 
afflicted, presenting as mostly hilar lymphadenopathy but also including pulmonary 
hyperternsion and obstructive and restrictive airway disease (Iannuzzi et al. 2011). Other 
major organ systems disturbed include the skin, the eye, the heart, and the nervous system 
with approximately 25 to 30% involvement (Iannuzzi et al 2011). Renal sarcoidosis is in fact 
rare with exact number relating prevalence difficult to come by. Unfortunately, the etiology 
for nephron-related disease is quite vast and it has been hard to delineate pure renal 
manifestations from simple metabolic disturbances (Berliner et al 2006). In order to 
understand the extent and pathogenesis of renal involvement, two central pathways for 
nephron insult has been validated including granulomatous deposition and deranged 
calcium management. While these pathways are by no means the only two routes of renal 
involvement, they are the most significant and the overriding themes for renal insult.  
3.1 Granuloma formation 
Many aspects of this process still require elucidation yet strong evidence reveals that 
granuloma formation centers on T cells reacting with unclear triggers and certain gene 
products to illicit cascades that either lead to complete resolution of inflammation or to 
irreversible fibrosis (Iannuzzi et al. 2007). Specifically, antigen presenting cells including 
macrophages with susceptible HLA or BTNL2 gene products present triggers including 
organic, inorganic, and infectious agents to the CD4 T cell. Once initiated, numerous 
peripheral cytokines, interleukins, and immune modulators steer T cells into a T Helper 1 or 
T Helper 2 response; where with the former, resolution of inflammation is more probable 
but with the later, fibrosis and irreversible damage is more probable (Iannuzzi et al. 2007, 
2011). This deposition of macrophages, giant cells, and T helper cells form the 
pathognomonic, non-caseating granulomas that defines sarcoidosis (Casella and Allon 1983) 
See Figure 1. In renal disease, these granulomas are primarily in the cortex but may also be 
found in the medulla or capsule (Casella and Allon 1983). This process is the basis for 
granulomatous interstitial nephritis, which will be further discussed subsequently.  
3.2 Deranged calcium management 
Despite the granulomatous inflammation that marks sarcoidosis, deranged calcium 
homeostasis has a greater effect on the kidneys than the invasive granulomas themselves. 
Activated pulmonary macrophages express 1-α hydroxylase, which has important 
implications in maintaining appropriate levels of calcium in the body. In normal physiology, 
calcium balance is attained through the intricate interactions of parathyroid hormone (PTH), 
calcium, phosphorus, and Vitamin D. PTH upregulates renal 1-α hydroxylase, a cytochrome 
P450 enzyme located in the proximal tubule, to metabolize 25-hydroxy vitamin D to 1, 25-
dihydroxy vitamin D, the bioactive form of Vitamin D, also known as calcitriol. Calcitriol, in 
turn, promotes calcium absorption in the intestines, kidneys, and bones. When calcium 
levels are adequate, normal physiological negative feedback mechanisms halt the PTH and 
calcitriol cycle. However, in sarcoidosis, extra-renal production of 1-α hydroxylase 
inappropriately increases calcitriol levels thereby increasing serum calcium and decreasing 
PTH. Unlike its renal equivalent, the granulomatous 1-α hydroxylase is immuned from the 
normal negative feedback mechanisms of hypercalcemia and is therefore unregulated,  
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(Iannuzzi MC et al. N Engl J Med 2007;357:2153-2165.) 
Fig. 1. Hypothesized Immunopathogenesis of Granuloma Formation.  
causing disturbed calcium homeostasis. This not only causes hypercalcemia, hypercalciuria 
and possibly subsequent nephrolithiasis and nephrocalcinosis, which itself is the most 
common cause of progressive renal failure. The clinical consequences of each imbalance 
range from trivial presentation to overt pathology including dehydration, renal colic, and 
end-stage renal disease. Diagnosis may be established by laboratory findings, 
ultrasonography, and computed tomography. General treatments incorporate adequate oral 
hydration, minimization of dietary calcium and vitamin D, avoidance of UV light exposure, 
and possibly corticosteroid therapy (Sharma 1996).  
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Hypercalcemia may cause decrease glomerular filtration rate by vasoconstricting the afferent 
arterioles and thereby decreasing renal blood flow (Berliner et al 2006). Additionally, it may 
cause tubular necrosis, tubulointerstitial non-granulomatous inflammation with calcium 
deposits ultimately causing nephrocalcinosis and chronic kidney disease (Berliner et al 2006). 
Hypercalciuria, which is three times as more common as hypercalcemia, predisposes patients 
to calcium oxalate nephrolithiasis, which may ultimately lead to obstruction or chronic 
pyelonephritis (Berliner et al 2006 and Sharma 1996). Renovascular complications as well as 
obstructive nephropathy will also be further discussed subsequently.  
4. Obstructive nephropathy 
Abnormal calcium metabolism is a well known feature of sarcoidosis. Hypercalcemia and 
hypercalcuria is related to endogenous vitamin D. It is suggested that excess vitamin D may 
result in increased intestinal calcium absorption and consequent hypercalcemia, 
hypercalcuria and renal calculi. Hypercalcuria is defined as using excretion of 300 mg/day 
in men or 250 mg/day in women, about 2-5% healthy adults exhibit hypercalcuria. 
Hypercalcuria is the most common renal manifestation. It is caused by glomerular filtration 
of excess blood calcium and suppression by high calcitriol levels on PTH activity. It affects 
50% of patients with sarcoidosis, often with an insidious onset because most patients remain 
normocalcemic. Sharma suggests that 10% of patients with sarcoidosis are diagnosed with 
hypercalcemia whereas 30% of patients with sarcoidosis show an increase in serum calcium. 
(Sharma, 1996)  
In 1988, Foster described eight patients where he described extra uveitis may be the 
presenting sign of sarcoidosis. It was the first study that suggested that there may be 
unexpected presenting signs of sarcoidosis. (Foster, 1988) One of these symptoms may be 
nephrolithiasis. In a study from Italy, the charts 618 patients with histologically proven 
sarcoidosis was reviewed in 1978-92 in order to identify nephrolithiasis as a presenting 
feature of sarcoidosis. (Rizzato et al 1995) The authors concluded that calculi were the 
presenting feature of sarcoidosis in 6 out of 618 patients (1%) and was the first manifestation 
of disease in 14 (2. 2%) of the patients. In another 9 patients who presented with pulmonary 
involvement, persistent hematuria or pyuria led to discovery of stones via ultrasound or 
intravenous pyelography. Given that this is an uncommon disease, there is a very small 
chance that a physician seeing a patient for the first time with a new kidney stone will later 
prove to be is sarcoidosis. In the literature, the overall prevalence of nephrolithiasis is 10% in 
patients with sarcoidosis. (Muther et al 1981 and Rizzato 1995) The incidence of 2.2% 
exceeds more than 20 times the expected yearly rate of renal calculi in the general 
population (36 per 100, 000 in women and 123 in men in Rochester (Johnson et al 1979), 122 
in California (Hiatt et al 1982) and 68 in Kyoto –Osaka. (Yoshida and Okada, 1990) In course 
of chronic sarcoidosis, approximately 10-13.8% of patients have at least 1 asymptomatic 
stone. (Lebacq, 1970) 
Treatment of hypercalcuria involves minimization of dietary calcium and Vitamin D, 
avoidance of UV exposure, and dietary oxalate restriction. This is because an increase in 
intestinal calcium absorption caused by excess in 1, 25 dihydroxyvitamin D may result in an 
increase in urinary oxalate excretion especially if diet is low in calcium. Overabsorption of 
calcium leaves less of this divalent cation to complex with oxalate in the proximal intestine 
so more oxalate is delivered to the colon in which anion is hyperabsorbed. Corticosteriods 
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are usually necessary to normalize these parameters as they can decrease inflammatory 
activity and reduce calcitriol syntheses.  
Retroperitoneal lymph nodes can enlarge sufficiently to cause urethral obstruction.  
(Frailly et al 1990). Sarcoidosis has also been shown to be responsible for bilateral 
hydronephrosis on the basis of retroperitoneal lymph node enlargement, with resolution 
after corticosteroid treatment. (Miyazaki 1995). 
5. Glomerular diseases associated with sarcoidosis 
Glomerular involvement in sarcoidosis is not very common. The spectrum of commonly 
reported glomerular diseases include focal segmental sclerosis, membranous 
glomerulonephritis (GN), mesangioproliferative glomerulonephritis, mesangiocapillary 
glomerulonephritis, IgA nephropathy and crescentric glomerulonephritis. (Sheffield 1997) 
The exact mechanisms of glomerular disease in sarcoidosis are not known. Due to the 
absence of a consistent glomerular pathology and a well described etiological pathway, 
most cases are believed to be coincidental associations. Broadly speaking, abnormalities in 
both the humoral and cellular immune system in sarcoidosis contribute to the development 
of immune complex –type glomerulonephritis which also explains why immunoglobulin 
and complement deposition are commonly observed in renal biopsies in sarcoidosis. (Gobel 
et al 2001). 
5.1 Membranous glomerulonephritis 
Overall, membranous glomerulonephritis (MGN) is the most commonly reported 
glomerular pathology. Amongst 39 cases of glomerular diseases reported in sarcoidosis, 
Vanhille et al found that 13 were MGN, largely occurring late in the course of overt disease. 
(Vanhille et al 1986) Khan et al. described a 56-yr-old woman with pulmonary sarcoidosis 
who developed heavy proteinuria. A renal biopsy revealed both interstitial granulomas and 
membranous glomerulonephritis. (Khan et al 1999) Rarely patients may be diagnosed to 
have sarcoidosis during the work up for secondary causes of nephrotic syndrome. 
Dimitriades et al. described a 13-yr-old girl who presented with the nephrotic syndrome and 
renal biopsy showed membranous nephropathy. (Dimitriades 1999) Typical subepithelial 
deposits were found with electron microscopy. Bilateral hilar adenopathy was present, 
which suggested sarcoidosis. The diagnosis was confirmed by a bone marrow biopsy, which 
disclosed noncaseating granulomas. The patient was treated with corticosteroids and 
cyclophosphamide, and her condition stabilized. In an experimental study, Maruyama et al, 
induced subepithelial deposits in pigs injected with heterologous antibodies to angiotensin 
converting enzyme (ACE). Confocal microscopy showed co localization of the granular 
deposits of ACE and anti ACE goat IgG on the outer aspect of glomerular basement. The 
authors conjectured that a similar autoimmune process may cause membranous GN in 
sarcoidosis. While traditionally idiopathic MGN is steroid resistant, most cases of MGN 
associated with sarcoidosis seem to respond to high dose steroid therapy especially if there 
is coexistent granulomatous interstitial nephritis (GIN) (Khan et al 1999). Others used pulse 
methylprednisolone plus oral cyclophosphamide to show remission of the nephrotic state. 
(Dimitriades et al 1999) See Figure 2. for histology of membranous nephropathy in 
sarcoidosis.  
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Fig. 2. (A) Immunofluorescence shows granular IgG deposits along the glomerular basement 
membrane consistent with membranous glomerulonephritis. (B) Left forearm biopsy with 
epithelioid granulomas. A star-shaped asteroid body is visible within a giant cell. 
Magnifications: x800 in A (IgG); x500 in B (hematoxylin and eosin). Gobel U et al. JASN 
2001;12:616-623 
5.2 Minimal change disease 
Nephrotic syndrome due to minimal change disease (MCD) also has been described in 
patients with sarcoidosis. Mundlein et al, described a patient with Grave’s disease with 
steroid dependent MCD who achieved complete remission with cyclophosphamide. 
(Mundlein et al 1996) Patient was subsequently diagnosed to have typical chest findings of 
pulmonary sarcoidosis. In contrast, Parry and Falk described a case of longstanding 
pulmonary sarcoidosis that later went on to develop steroid resistant MCD not responding 
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to high dose steroids or cyclophosphamide. (Parry et al 1997) The patient had to be started 
on cyclosporine which was given for a year and a sustained remission was attained. 
Spontaneous occurrence and remission of heavy proteinuria coinciding with the relapse of 
the disease is also well described. (Mery 2005) The authors postulated that there is a 
functional and transient increase of glomerular permeability to proteins secondary to release 
of vascular permeability factor like lymphokines by activated T cells.  
5.3 Crescentic glomerulonephritis 
Crescent Glomerulonephrits (GN) has also been frequently reported in patients with 
sarcoidosis and co-existing ANCA associated vasculitis. ANCA are autoantibodies found in 
some autoimmune diseases, recognized by their reactivity with cytoplasmic antigens in 
neutrophils; two groups are recognized: c-ANCA, reacting with proteinase 3, is found in 
polyangiitis and Churg-Strauss syndrome; p-ANCA, reacting with myeloperoxidase is 
found in Wegener granulomatosis. Auinger et al described a patient with rapidly 
progressive glomerulonephritis and hepatosplenomegaly with no prior diagnosis of 
sarcoidosis whose renal biopsy showed crescentic GN. (Auinger et al 1997) Diagnosis of 
sarcoidosis was made with raised angiotensin converting enzyme (ACE) levels and both 
liver and kidney biopsies showing interstitial noncaseating granulomas. Patient was started 
on high dose steroids with which renal function improved. Subsequently, the patient 
developed anti- myeloperoxidase (MPO) antibodies. In contrast, Ahuja et al reported a 
patient with crescentic GN in the setting of Wegener's granulomatosis (WG). (Ahuja et al 
1996). Patient responded well to long term oral cyclophosphamide treatment. Subsequently, 
the patient developed biopsy-confirmed pulmonary sarcoidosis months later. Given such 
close associations, it is believed that these sarcoidosis and granulomatous vasculitis like WG 
may have some common mechanisms. See Figure 3.  
5.4 Other glomerular diseases 
Rare associations of sarcoidosis with post-infectious GN have also been noted. Michaels et 
al. described two patients with sarcoidosis : one with recent history of pneumonia and 
other with elevated antistreptolysin O titres who developed acute renal failure with active 
urinary sediments and nephrotic range proteinuria (Michaels et al 2000). Biopsies 
disclosed diffuse endocapillary proliferative GN with hump-like epithelial deposits. Both 
patients responded well to corticosteroids with resolution of proteinuria and azotemia. 
Similarly IgA nephropathy (IgAN), coexisting with sarcoidosis is not unusual given the 
wide prevalence of IgAN. Taylor and Nishiki described a case of IgAN in sarcoidosis 
typically presenting as nephritic syndrome that responded well to steroids. (Taylor at el 
1996 and Nishiki et al 2010) Renal amyloidosis (AA type) has also noted in patients with 
long standing sarcoidosis with the classical presentation of steroid resistant nephrotic 
syndrome with slow progression to end stage renal disease. (Tchenio et al. 1996 and 
Rainfray et al 1988). 
6. Tubulointerstitial diseases 
After excluding abnormalities affecting calcium homeostasis, tubulointerstitial diseases  
are the most commonly encountered renal abnormalities in sarcoidosis. They are  
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Fig. 3. (A) Roentgenogram showing bilateral hilar adenopathy in a patient with sarcoidosis. 
(B) Extracapillary glomerulonephritis with crescent formation. Magnification, x500 (periodic 
acid-Schiff). Gobel U et al. JASN 2001; 12:616-623 
histopathologically described as granulomatous interstitial nephritis (GIN). Approximately 
20% of patients with sarcoidosis show granulomatous inflammation in the kidney (Sheffield 
1997) although values range from 15 to 40% (Mery 2005) reflecting differences in the 
indication for renal biopsies. In many instances, patients may be clinically silent and GIN 
may present with concomitant findings with well known clinicopathological syndromes. 
The variability in incidence of GIN also reflects sampling error in detecting scarce 
granulomas especially in inadequate biopsy specimens.  
Overall GIN is a rare histologic diagnosis seen in 0. 5 and 0. 9% of native renal biopsies and 
0. 6% of renal transplant biopsies (Joss et al 2007). Possible etiologies include medications, 
infections, sarcoidosis, Sjogren’s syndrome, crystal deposits, paraproteinemia, Wegener’s 
granulomatosis and idiopathic causes. Drugs implicated include anticonvulsants, 
antibiotics, nonsteroidal anti-inflammatory drugs, allopurinol, and diuretics. Mycobacteria 
and fungi are the main infective causes and seem to be the main causative factor in cases in 
renal transplants or in countries with high prevalence of tuberculosis. In the largest 
collection of data so far on this disease, Joss et al noted 18 cases of GIN from of etiologies 
such as sarcoidosis (n=5), drug induced (n=2), idiopathic (n=9) and tubulointerstitial 
nephritis with uveitis (n=2). The most common presentation of GIN was advanced renal 
failure with minimal proteinuria. (Joss 2007) 
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Despite great clinical variability, the most common clinical syndrome associated with 
sarcoidosis and GIN is chronic kidney disease with decline in renal function usually over 
weeks to months (Jean-Philllipe 2005). Acute renal failure as an initial presentation is also 
well known (O’Riordan et al 2001). Renal dysfunction may progress at variable rates but can 
irreversibly progress to end stage renal disease despite high dose glucocorticoid treatment. 
(Tsiouris et al 1999) Consistent with a pattern of tubulointerstitial disease, proteinuria is 
either absent or mild. Urine analysis shows leucocytes and granular casts. Rarely, patient 
may present as frank hematuria lasting several weeks. (Mills et al 1994) Functional tubular 
abnormalities can occur in as much as 50% of cases of sarcoidosis when aggressively 
investigated which include renal glycosuria, urinary sodium and potassium wasting, 
Fanconi’s Syndrome, decreased urinary concentration ability, proximal or distal tubular 
acidosis. (Muther et al 1981) It is uncertain whether the presence of interstitial lesions solely 
contributes to these abnormalities but hypercalcemia and hypergammaglobulinemia also 
play a pathogenic role. (Mery, 2005) 
GIN is usually associated with enlarged kidneys mimicking polycystic kidney disease or 
renal carcinoma. (Mery, 2005) Renal sonogram shows bilateral renal masses which are either 
hyper- or hypoechoic in comparison to adjacent renal parenchyma. Computer tomogram 
shows the renal masses to be low intensity. A Gallium-76 citrate scan commonly reveals 
increased uptake suggesting active granulomatous inflammation. (Mery and Kenouch, 1988) 
Serum ACE concentration is a poor marker of active renal lesion and may even be normal in 
active GIN with severe renal failure. (Hannedouche et al 1990) 
In most cases, a diagnosis of GIN is made in the context of typical extra-renal manifestations 
of sarcoidosis and/or hyperkalemia. Rarely renal involvement may be isolated and 
preceding other sites of the disease for months to years. Some have even considered isolated 
GIN as a localized form of sarcoidosis. In such isolated cases, it is important to rule out drug 
induced interstitial nephritis which is far more easily treatable cause of GIN that sarcoidosis 
itself. (Muther et al 1981) Another syndrome commonly associated with Sjogren’s Syndrome 
but also reported with sarcoidosis is the “TINU syndrome or the Dobrin Syndrome 
(Sinnamon et al 2008) which is characterized by acute interstitial nephritis, anterior uveitis 
and epitheliod granulomas in bone marrow and lymph nodes. The renal lesion consists of 
interstitial infiltrates mainly composed of mononuclear cells and few eosinophils. Although 
no interstitial granulomas are seen in TINU, the interstitial cell infiltrate is the same as a 
sarcoid granuloma. Therefore it is possible that some cases described as Dobrin syndrome 
may be atypical forms of sarcoidosis.  
Analyzing all cases of GIN, Joss et al, noted that the background diagnosis of sarcoidosis 
was known in only 1 of 5 patients of GIN who eventually were categorized as sarcoid GIN. 
Mean age of presentation was 56. 8 years. ACE levels were elevated in a minority of patients 
(1 out of 5) and hypercalcemia was seen in only 2 patients. Pulmonary findings of hilar 
lymphadenopathy was seen in only 1 patient and one had the TINU syndrome.  
(Joss et al 2007) 
Renal pathology of GIN consists of the typical non-caseating granuloma widely distributed 
throughout the cortex and the medulla, although the density of these lesions may differ 
from patient to patient. (Mery 2005) The sarcoid granuloma consists of lymphocytes, 
mononuclear, cells and plasma cells. The center of the granuloma consists of epitheliod and 
www.intechopen.com
 Chronic Kidney Disease 
 
96
multinucleate giant cells both of which are derived from activated macrophages. 
Multinucleate giant cells are formed by the coalescence of epitheliod cells. Lymphocytes 
largely consist of T-helper cells (CD 4+) in the center and CD 8+ lymphocytes in the 
periphery. Some granulomas have small arteries in their center. Although granulomas may 
also form in drug induced interstitial nephritis it is less well formed than in sarcoidosis. 
Varying degrees of fibrosis may also be present. The severity of fibrosis correlates with 
tubular atrophy and degeneration. In the absence of any predominant glomerular 
pathology, the glomeruli are either normal or show mesangial hypertrophy and thickening 
of the basement membrane. Electron microscopy may show fusion of epithelial foot 
processes (Farge et al 1986). However, there are no significant immune deposits in either the 
glomeruli or tubules as seen by immunoflourescent microscopy. In a significant number of 
cases, immunoflourescence with anti-ACE serum showed localization in the sarcoid 
granuloma in addition to normal staining of the brush border of the proximal tubules. (Mery 
et al 1988) See Figure 4.  
 
Fig. 4. Renal biopsy showed a granulomatous interstitial nephritis with a broadened 
interstitial, cellular infiltrates and granuloma with typical multinucleated giant cells 
(arrowheads). Kettritz R et al. Nephrol. Dial. Transplant. 2006; 21:2690-2694 
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In contrast to conventional pathological dogma, Joss et al showed that asteroid bodies and 
calcification were not common in sarcoid GIN. (Joss et al 2007) Interestingly, asteroid bodies 
were seen in 1 case of drug induced AIN. However, lymphocyte cuffing and giant cell 
infiltration were prominent in sarcoid granulomas in the kidney. Necrosis and eosinophil 
infiltration of the interstitum was more common in drug induced GIN as compared to 
sarcoidosis. It is now believed that idiopathic GIN, TINU and sarcoidosis represents a 
clinicopathological spectrum and that idiopathic GIN or TINU may subsequently develop 
typical extra-renal manifestations of sarcoidosis.  
6.1 Treatment  
The mainstay of treatment of sarcoid GIN is glucocorticoids. Initial treatment requires a 
daily dose of prednisone or prednisolone preferably 1-1. 5 mg/kg. Response to treatment 
can often be dramatic in terms of improvement of renal insufficiency. The best response to 
glucocorticoids was noted in a study by Mahevas et al. in which 47 patients with renal 
sarcoid received prednisolone while 10 also received pulse methylprednisolone. (Mahevas 
et al 2009) The authors concluded that at 24 months, a complete and partial remission 
occurred in 30 and 5 patients respectively. But no response was noted in patients with 
severe interstitial fibrosis of greater than 50%. Underlying functional tubular dysfunction 
improves with progressive drop in serum creatinine. An important point to realize here is 
that steroid treatment has to be prolonged and must exceed at least 6 months as 
nephropathy relapses very frequently with short term therapy (Gene and Cheviot 1988). A 
commonly followed strategy is to give the initial dose for 2 months followed by progressive 
taper and switching to an alternate –day therapy. A maintenance therapy period for 1 year 
at least is recommended. Serial renal biopsies have shown a regression of granuloma in 
conjunction with improvement of renal function (Farge et al 1986) although given the 
variability in results (Gene and Cheviot 1988) routine biopsies after starting steroids is not 
recommended. Treatment in advanced disease is often associated with interstitial fibrosis 
along with focal segmental glomerulosclerosis and vascular lesions. However, vascular 
lesions are more common with long term corticosteroid therapy and are associated with 
delayed development of hypertension which is a major contributor to progression of renal 
failure. (Mery and Kenouch 1988) 
While analyzing outcomes of steroid treatment in a heterogeneous population of GIN, Joss 
et al, presented data of 16 patients of which 5 were labeled as sarcoidosis. Patients were 
treated with prednisolone (starting dose of 0. 55mg/kg) (Joss et al 2007) for a mean period of 
25 months and then followed up for a period of 45 months. Overall, renal function stabilized 
or improved at the end of the study with mean GFR improving from 21 to 56 ml/min. One 
patient who was on dialysis at the beginning of therapy was able to discontinue dialysis 
within 3 months. Six patients relapsed on dose reduction of which 4 were sarcoid GIN who 
required azathioprine to break steroid dependence. Sarcoid patients required longer 
treatment (36 months) as compared to idiopathic or TINU patients. The greatest renal 
recovery occurred in the first year of treatment. There was no difference in renal outcome 
when analyzing the degree of interstitial fibrosis. Age less than 60 years was associated with 
a better outcome. Table 1 summarizes data on treatment of GIN in some important studies 
so far.  
Long term results with steroid therapy in sarcoid GIN have not been rigorously tested in 
randomized controlled trials. In a large case series of 39 patients with sarcoid renal disease,  
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Parameter Joss et al Robson et al. 
O’Riordan 
et al.  
Hannedouche 
et al.  
Brause 
et al.  








Age (yr) 55 56 69 48 to 71 62 61 
Male gender (%) 61 56 71 60 50 60 
Renal function at 
baseline 
      
BaselineCC 
(ml/min) 




373 357 420 NA 566 396 
Hypercalcemia 3/18 3/16 2/7 0/5 2/6 1/5 
Raised serum 
ACE 
4/17 4/15 3/7 1/5 4/4 1/5 
Improved renal 
function 
17/18 15/16 5/7 4/5 6/6 5/5 
Long-term RRT 0/18 0/16 2/7 0/5 0/6 0/5 
Prednisolone (%) 89 88 100 100 100 100 
Mean follow-up 
(mo) 
45 48 25 35 75 NA 
Renal function at 
last visit 
      
ECC (ml/min) at 
end of therapy 
56 53 22 20 NA NA 
Creatinine 
(μmol/L) at end 
of study 
159 159 296 NA 192 225 
1 Data excluding the two cases of drug-induced GIN.  
Table 1. Comparison on treatment of GIN in literature. 
17 patients with biopsy-proven tubulo-interstitial nephritis with significant renal 
impairment were analyzed over a one year period of corticosteroid therapy. (Robson et al 
2003). All patients were initially started on prednisolone at 0. 5 mg/kg body weight at a 
daily dose of 30–60 mg which was tapered by 5 mg each week once the renal function has 
improved and/or stabilized. Thereafter, patients were maintained on 5–7. 5 mg daily 
indefinitely. Mean duration of study was 84 months. Estimated glomerular filtration rate 
(eGFR) at baseline was 26. 814 ml/min which improved to 49. 65. 2 ml/min (P<0. 01) at 1 
year, and 47. 96. 8 ml/min (P<0. 05) at last review. Interestingly, the response to treatment 
was similar regardless of the degree of renal impairment at baseline, race and the degree of 
tubulo-interstitial scarring on renal biopsy. Three patients developed side effects that could 
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be attributed to steroids which included acute psychosis and type 2 diabetes. Long term use 
of corticosteroids, especially in adolescents, can cause substantial side effects including 
diabetes, growth retardation and cataract. Alternative agents that have been attempted in 
treating sarcoid GIN include mycophenolate (Moudgil 2002) and mizoribine (Rajakariar et al 
2006 and Ito et al 2009) which are limited to case reports and have been primarily used in 
pediatric patients to break steroid dependence or ameliorate significant side effects. Other 
agents which have been tried in systemic extra-renal sarcoidosis include mycophenolate 
mofetil, methotrexate, azathioprine, antimalarials, and phosphodiesterase inhibitors such as 
pentoxifylline and thalidomide although no data on treating renal sarcoidosis exists. 
(Baughman 2003) There has been great interest in the use of TNF-antagonists as another 
modality to treat sarcoid GIN in order to avoid use of steroids. TNF-alpha, which is 
expressed by monocytes, is critical in the development of these noncaseating granulomas. 
TNF-alpha receptor antagonists have also been shown to prevent the initiation and 
perpetuation of inflammation and subsequent interstitial fibrosis. Etanercept is a soluble 
TNF-alpha receptor fusion protein that binds TNF-alpha. Infliximab and adalimumab are 
monoclonal antibodies that bind specifically to and neutralize TNF-alpha. While etanercept 
is an ineffective agent in the treatment of systemic sarcoidosis, (Ulz et al 2003) infliximab has 
been shown to be effective in a case of renal sarcoid. Thumfart et al, described the case of a 
boy presenting with severe arterial hypertension and acute renal failure caused by an 
isolated sarcoid granulomatous interstitial nephritis. Renal function improved initially with 
prednisone treatment but later, the patient showed signs of severe steroid toxicity and 
progressive renal failure. Monthly treatment with infliximab was initiated resulting in a 
steady improvement in renal function and resolution of renal granulomata, as well as 
reduction in antihypertensive medication. (Thumfart 2005) Ahmed et al presented a patient 
with acute renal failure due to isolated granulomatous infiltration of the renal parenchyma. 
(Ahmed et al 2007) Renal biopsy showed granulomatous interstitial nephritis with 
noncaseating granulomas. There was no evidence of extrarenal sarcoid involvement. 
Prednisone 60mg daily resulted in significant improvement in renal function. Due to 
recurrent flares while tapering the prednisone and steroid toxicity, treatment with 
infliximab was instituted and resulted in stabilization of renal function. This case 
demonstrated that steroid-dependant or refractory renal sarcoidosis cases may respond to 
infliximab. We recently reported the case of a 46-year-old woman with multi-organ 
sarcoidosis, type 2 diabetes, subnephrotic-range proteinuria, hypertension and recurrent 
episodes of hypercalcemia-induced acute kidney injury who was referred for evaluation of 
worsening renal function and nephrotic range proteinuria. (Gupta et al 2008) A kidney 
biopsy showed sarcoid GIN with moderate-to-severe chronic tubulointerstitial disease, 
hypertensive vasculopathy, and diabetic glomerulosclerosis. Because steroids had caused 
multiple side effects including diabetes, hypertension and obesity and attempts to wean 
steroids had caused hypercalcemia and acute renal failure, Adalimumab (HumiraTM) 40 
mg/0. 8 cc weekly for 6 months was initiated. After 6 months of treatment with 
adalimumab, serum creatinine improved from 345 μmol/L (3. 9 mg/dL) to 1. 8 mg/dl (her 
baseline for years) and proteinuria improved from 10 g/day to 3. 5 g in 24 hours 
respectively. A repeat biopsy showed persistent diabetic glomerulosclerosis, moderate 
chronic tubulointerstitial inflammation with complete resolution of interstitial epitheliod 
granulomas. Although adalimumab and infliximab are generally safe, some side effects 
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include risk of lymphoma and reactivation of latent tuberculosis (Denys et al 2007). These 
agents may hold promise for the future once large scale randomized studies are available to 
show consistent benefits with minimal side effects.  
7. Renovascular diseases associated with sarcoidosis  
Renovascular diseases secondary to sarcoidosis are distinctly rare and attributed to a form 
of secondary vasculitides. Systemic vasculitis associated with sarcoidosis has been 
reported as an isolated entity in the literature after excluding other common causes of 
vasculitis. It is predominantly large vessel vasculitis although few instances of small 
vessel vasculitis have been reported. In a large case series and review of literature on 
sarcoid vasculitis, Fernandes et al, noted that most cases were children and clinical 
presentation resembled hypersensitivity vasculitis, Takayasu’s arteritis, polyarteritis 
nodosa or microscopic polyangitis. (Fernandes 2000) Clinical features included fever, 
peripheral adenopathy, hilar adenopathy, rash, pulmonary parenchymal disease, 
musculoskeletal symptoms, and scleritis or iridocyclitis with biopsy showing necrotizing 
sarcoid granulomata. Interestingly, no renal involvement was noted. Notably the authors 
found large vessel vasculitis largely in the African American population while small 
vessel vasculitis predominantly affected white races. Godin et al described a known case 
of pulmonary sarcoidosis with persistent hypertension. (Godin et al 1980) Diagnostic 
evaluation for renovascular hypertension included aortography which showed severe 
stenosis of right renal artery. Surgical exploration showed extensive periaortic and 
perirenal fibrosis with extrinsic compression of renal artery. Pathological examination of 
the kidney revealed epitheloid infiltration of the adventia of renal artery suggestive of 
sarcoid angitis. Surgical biopsy was performed on both kidneys. The right kidney, 
protected by arterial stenosis, was slightly altered, while the left kidney showed extensive 
interstitial, tubular, and glomerular lesions which included focal and segmental 
hyalinosis. Marcussen et al, reported an autopsy case of a middle aged man who died of 
myocardial infarction secondary to fulminent vasculitis. (Marcussen and Lund 1989) 
Pathology showed widespread giant cell vasculitis with simultaneous involvement of the 
renal arteries, veins, and arterioles along with typical interstitial sarcoid granuloma. 
Shintaku et al, showed granulomatous inflammation of small renal vessels and crescentric 
GN on the autopsy of a patient with pulmonary hemorrhage and rapidly progressive 
renal failure. (Shintaku et al 1989) Thus, sarcoid angitis, especially causing small vessel 
vasculitis in the kidney may represent a very severe form of sarcoidosis. In their review, 
Fernandes et al, noted that four out of six patients responded well to steroid treatment 
alone but had relapses when attempts were made to taper or withdraw steroids. 
(Fernandes 2000) Frequently, there is an overlap between sarcoidosis and well known 
causes of granulomatous vasculitis. For instance, Watson et al described a case of 
longstanding pulmonary sarcoidosis presenting with rapidly progressive renal failure 
with p-ANCA positivity. (Watson 1996) Renal biopsy demonstrated focal and segmental 
fibrinoid necrosis with crescentric GN and focal fibrinoid necrosis in arterial wall, but no 
granulomata and pauci-immune deposits on immunofluorescence. Unlike patients with 
ANCA positive vasculitis, the index case responded poorly to pulse steroids and 
cyclophosphamide and progressed rapidly to end stage renal disease.  
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8. Kidney transplantation in patients with sarcoidosis  
The usual cause of end stage renal disease in sarcoidosis requiring renal replacement 
therapy is usually due to hypercalcemic nephropathy rather than granulomatous interstitial 
nephritis or a glomerular disease. The outcome in renal transplantation in patients with 
sarcoidosis has been described in the literature. The first recurrence of sarcoid GIN in renal 
allograft was diagnosed 6 years after deceased donor kidney transplantation in a patient 
that was diagnosed with GIN before transplantation (Shen et al 1986). A recent French study 
aimed to describe a multicenter experience with kidney transplantation in patients with 
sarcoidosis. (Aouizerate et al 2010) In this study, the authors retrospectively identified 18 
patients who underwent renal transplantation. Patient medical charts, demographics were 
reviewed. The median time between the last sarcoidosis episode and renal transplantation 
was 78 (8 to 900) months. Only 3 out of 18 patients had been on immunosuppression prior to 
transplantation. Vast majority of the patients had in the past received steroids and other 
immunosuppression for their sarcoid before transplantation. Renal disease was attributable 
to biopsy proven renal sarcoid in 10 out of the 18 patients and was attributed to other causes 
in 8 patients. Mean age of transplantation was 43. 5 +/- 11 years. 17 out of 18 patients had a 
deceased donor transplant. Mean donor age was 36. 5 +/ 15 years. Mean cold ischemia time 
was 16. 6 +/- 8 hours. 11 patients received induction therapy with anti-thymocyte globulin 
or Il-2 receptor antagonists. Maintenance immunosuppression included calcineurin inhibitor 
(CNI) for all patients, mycophenolate mofetil or azathiporine, sirolimus and corticosteroids 
for 16 out of the 18 patients. At the end of the 42 month follow up period, patient and death 
censored graft survival was 94. 4% and mean GFR was 60 cc/min per 1. 73 m2. Recurrence 
of sarcoidosis after renal transplantation was observed in 5 (27%) of patients. The median 
period between renal transplantation and recurrence was 13 months and four of five 
patients exhibited recurrence in the first 18 months after renal transplantation. Recurrences 
involved in the same organ in four of five patients and included renal involvement in three 
patients and lung and liver involvement in one patient. Mean GFR at end of follow-up was 
significantly lower in the three patients with recurrence than that for the entire cohort. (31 
versus 60 cc/min per 1. 73 m2). Analysis of the recurrences showed that they occur in the 
first 18 months after transplantation. Primary disease related to sarcoidosis was strongly 
associated with recurrence (40% in the group with renal sarcoidosis versus 12. 5% in a group 
with a primary nephropathy, and median period between last episode of sarcoidosis and 
renal transplantation was shorter in the case of sarcoidosis recurrence (42 versus 78 months 
respectively). This study showed that patients with initial renal involvement display 
sensitivity to disease recurrence in allograft. The incidence of recurrence was significant as 
all patients were maintained on triple immunosuppressive therapy including steroids and 
mycophenolate mofetil. This study showed that renal transplant can be conducted safely in 
transplant patients with sarcoidosis, but recurrences do occur and affect overall graft 
outcome.  
Kukura reported a case of recurrence of sarcoidosis in the renal allograft during pregnancy. 
(Kukura et al 2004) This was a 27 yr old female diagnosed with sarcoidosis at age 14 by 
lacrimal and parotid gland biopsy. 4 years after presentation, she developed hypertension 
and renal insufficiency. Kidney biopsy showed interstitial nephritis and nephrosclerosis, but 
no granulomas. Patient was eventually started in hemodialysis and underwent kidney 
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transplantation with excellent graft function with a creatinine of 1. 32 mg/dl and a negative 
urinalysis. Patient was maintained on cyclosporine, azathioprine and prednisone 25 mg by 
mouth daily. 2 years after transplantation once the steroids were withdrawn, patient 
continued to have good kidney function with an allograft biopsy showing mild chronic 
allograft nephropathy only. Immunosuppression consisted of azathioprine and 
cyclosporine. At 3 years after kidney transplantation, patient became pregnant. 29 weeks 
into pregnancy, renal function worsened. Biopsy showed numerous noncaseating 
granulomas bound to the arteries, initial arteritis in one artery, mild interstitial mononuclear 
inflammation and tubulitis. Graft function improved with pulse methylprednisolone and 
tapered steroids were used. After delivery, renal allograft biopsy was performed 6 months 
which showed baseline disease of mild chronic allograft nephropathy and sporadic 
granulomas. This case demonstrates that steroid withdrawal after kidney transplantation 
may lead to sarcoidosis recurrence.  
The implication that sarcoid reflects a disease phenomena related to the immunologic 
stimulus makes sarcoidosis an unlikely diagnosis to be made in an immunosuppressed 
patient such as an organ transplant recipient. However, Schmidt et al showed that after 
kidney transplantation, sarcoidosis can occur in the lung and pleura. (Schmidt et al 1999) In 
this case, a 41 yr old with history of IgA nephropathy and no past medical history received a 
living related kidney transplant and had been receiving tacrolimus therapy. He was found 
to have a large pleural effusion 17 months after kidney transplant. Diagnosis of sarcoidosis 
was established by identifying noncaseating granulomas, some with multinucleated giant 
cells in the pleural and lung tissue. All viral and bacterial workup was negative. The 
effusion resolved after initiating corticosteroid therapy. One month into therapy, the 
effusion resolved and patient continued to be asymptomatic twenty months after therapy. 
The authors did not speculate on the pathogenesis of granuloma formation since both 
tacrolimus and corticosteroids interfere with T lymphocyte function and granuloma 
formation. They speculated that activation of tissue chemokines of the IP-10 type during the 
posttransplant period, along with subsequent recruitment of lymphocytes and macrophages 
may have resulted in the sarcoidosis.  
9. Conclusion 
Sarcoidosis is a disease that primarily affects the reticuloendothelial system but can affect all 
tissues and organ systems. In this chapter, we described the effects of sarcoidosis on the 
kidneys. This disease affects patients worldwide and is defined pathologically by the 
presence of noncaseating granulomas in the involved tissue. The etiology of sarcoidosis has 
yet to be determined but some have proposed a possible infectious etiology. Commonly 
sarcoid patients present with hypercalcemia, hypercalcuria, and nephrolithiasis due to the 
overproduction of calcitriol from the epitheliod granulomas. We also described the rare 
glomerular and renovascular manifestations of sarcoidosis. Granulomatous interstitial 
nephritis is most commonly associated with sarcoidosis. It is a histological diagnosis and 
can be treated with both steroids and TNF-alpha antagonists. Kidney transplantation is safe 
in patients with sarcoidosis but we must keep in mind the disease can recur in the allograft. 
In conclusion, sarcoidosis is a complex disease and presents both a diagnostic and 
management challenge to the physician.  
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